Deutsche Bank AG Takes Position in Gritstone Oncology Inc (NASDAQ:GRTS)

Deutsche Bank AG acquired a new stake in Gritstone Oncology Inc (NASDAQ:GRTS) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 29,056 shares of the company’s stock, valued at approximately $448,000. Deutsche Bank AG owned approximately 0.10% of Gritstone Oncology at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of GRTS. Citigroup Inc. acquired a new position in Gritstone Oncology in the 4th quarter valued at $28,000. Strs Ohio acquired a new stake in shares of Gritstone Oncology during the 4th quarter worth $29,000. American International Group Inc. acquired a new stake in shares of Gritstone Oncology during the 4th quarter worth $70,000. D. E. Shaw & Co. Inc. acquired a new stake in shares of Gritstone Oncology during the 4th quarter worth $157,000. Finally, Squarepoint Ops LLC acquired a new stake in shares of Gritstone Oncology during the 4th quarter worth $444,000. 48.83% of the stock is currently owned by hedge funds and other institutional investors.

NASDAQ:GRTS traded down $0.14 during trading hours on Friday, hitting $9.83. The company’s stock had a trading volume of 102,433 shares, compared to its average volume of 187,720. The company has a quick ratio of 9.57, a current ratio of 9.57 and a debt-to-equity ratio of 0.13. The firm has a market capitalization of $354.88 million and a PE ratio of -1.35. Gritstone Oncology Inc has a twelve month low of $8.75 and a twelve month high of $32.90.

Gritstone Oncology (NASDAQ:GRTS) last posted its earnings results on Monday, May 13th. The company reported ($0.62) EPS for the quarter, beating the consensus estimate of ($0.65) by $0.03. The firm had revenue of $1.35 million during the quarter, compared to the consensus estimate of $1.20 million. On average, analysts anticipate that Gritstone Oncology Inc will post -2.39 EPS for the current fiscal year.

Several analysts have recently issued reports on GRTS shares. Zacks Investment Research raised Gritstone Oncology from a “sell” rating to a “hold” rating and set a $12.00 target price on the stock in a report on Tuesday, May 14th. HC Wainwright assumed coverage on Gritstone Oncology in a research note on Thursday, March 7th. They issued a “buy” rating and a $17.00 price objective on the stock. Raymond James assumed coverage on Gritstone Oncology in a research note on Thursday, March 14th. They issued an “outperform” rating and a $20.00 price objective on the stock. Cowen reaffirmed a “buy” rating on shares of Gritstone Oncology in a research note on Monday, May 13th. Finally, Berenberg Bank assumed coverage on Gritstone Oncology in a research note on Wednesday, March 27th. They issued a “buy” rating on the stock. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $20.50.

ILLEGAL ACTIVITY WARNING: This news story was originally published by Sundance Herald and is the sole property of of Sundance Herald. If you are reading this news story on another domain, it was copied illegally and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this news story can be read at https://sundanceherald.com/2019/06/14/deutsche-bank-ag-takes-448000-position-in-gritstone-oncology-inc-grts.html.

Gritstone Oncology Profile

Gritstone Oncology Inc, an immuno-oncology company, engages in developing tumor-specific cancer immunotherapies to fight various cancer types. Its lead product candidate is GRANITE-001, which is in Phase I/II clinical trial for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers.

Further Reading: Stock Selection – What is cash flow?

Institutional Ownership by Quarter for Gritstone Oncology (NASDAQ:GRTS)

Receive News & Ratings for Gritstone Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gritstone Oncology and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply